{"title":"Perspectives on the Treatment of Mantle Cell Lymphoma and Follicular Lymphoma in 2015 and Beyond","authors":"Juliette B. Bell","doi":"10.33590/emjhematol/10312591","DOIUrl":null,"url":null,"abstract":"Prof Martin Dreyling opened the symposium by providing an overview of the current status of mantle cell lymphoma (MCL) and the current guidelines for treatment. Prof Steven Le Gouill discussed emerging tools to improve the diagnosis and monitoring of patients such as the assessment of minimal residual disease and the optimal incorporation of new technologies into the treatment pathway. Prof Marek Trněný then spoke about new treatment options for MCL and the improved survival that has been reported from certain combination therapies. Prof Martin Dreyling closed the MCL session.\n\nProf Gilles Salles introduced the follicular lymphoma (FL) session by explaining how the treatment landscape of FL has recently changed with the advent of anti-CD20 therapies. Prof Paulo Corradini then described the current treatment landscape in FL and Dr Jehan Dupuis spoke about the use of positron emission tomography (PET) at the start, interim, and end of treatment for FL. Prof Gilles Salles described the challenges of incorporating new treatment recommendations and tools for FL within current treatment options, and then summarised and closed the event.","PeriodicalId":326555,"journal":{"name":"EMJ Hematology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2015-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EMJ Hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33590/emjhematol/10312591","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Prof Martin Dreyling opened the symposium by providing an overview of the current status of mantle cell lymphoma (MCL) and the current guidelines for treatment. Prof Steven Le Gouill discussed emerging tools to improve the diagnosis and monitoring of patients such as the assessment of minimal residual disease and the optimal incorporation of new technologies into the treatment pathway. Prof Marek Trněný then spoke about new treatment options for MCL and the improved survival that has been reported from certain combination therapies. Prof Martin Dreyling closed the MCL session.
Prof Gilles Salles introduced the follicular lymphoma (FL) session by explaining how the treatment landscape of FL has recently changed with the advent of anti-CD20 therapies. Prof Paulo Corradini then described the current treatment landscape in FL and Dr Jehan Dupuis spoke about the use of positron emission tomography (PET) at the start, interim, and end of treatment for FL. Prof Gilles Salles described the challenges of incorporating new treatment recommendations and tools for FL within current treatment options, and then summarised and closed the event.
Martin Dreyling教授首先概述了套细胞淋巴瘤(MCL)的现状和目前的治疗指南。Steven Le Gouill教授讨论了用于改善患者诊断和监测的新兴工具，例如评估最小残留疾病和将新技术最佳地纳入治疗途径。Marek教授Trněný随后谈到了MCL的新治疗方案，以及某些联合疗法所提高的生存率。Martin Dreyling教授结束了MCL会议。Gilles Salles教授介绍了滤泡性淋巴瘤(FL)会议，他解释了最近随着抗cd20疗法的出现，滤泡性淋巴瘤的治疗前景是如何发生变化的。paul Corradini教授随后描述了目前FL的治疗前景，Jehan Dupuis博士谈到了在FL治疗的开始、中期和结束时使用正电子发射断层扫描(PET)。Gilles Salles教授描述了在当前治疗方案中纳入新的治疗建议和FL工具的挑战，然后总结并结束了这次活动。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
